Abstract:

Objective To evaluate the efficacy of sorafenib in the treatment of hepatocellular carcinoma（HCC） through combined with peripheral circulating

tumor cell（CTC） and to improve the recognition of CTC in HCC. Methods CTCs of two HCC patients were isolated by SET-iFISH technique and were identified by i-FISH. Then we analyzed the patients’ clinical manifestation and long-term survival with CTC. Results CTCs of HCC were marked as CK-/DAPI+/FISH（CEP8 single）+/CD45-. We separated 2 patients’ peripheral blood （7.5 ml） in three consecutive days. Patient 1 had 2 CTCs，however， we had not found CTC in patient 2’ s blood. Till now， patient 2 have disease-free survival of 13 months. Conclusion Combination with CTCs can be an effective and noninvasive method to analyze the efficacy of sorafenib in the treatment of HCC. It can provide a new prospect in the diagnosis and treatment of HCC.